BUSINESSFINANCIAL TIMES WORLD
Eli Lilly and Novo Nordisk raise profit outlook as weight-loss drug demand soars
Eli Lilly and Novo Nordisk raised their profit outlooks due to increased demand for weight-loss drugs. Investors are showing a dim view of Novo Nordisk's over-reliance on obesity treatments, causing diverging share prices between the two drugmakers.
Related Signal
Adjacent reporting
- Eli Lilly beat earnings and raised its forecast as weight loss drug sales surged
- Novo Nordisk Shares Surge on New Obesity Drug Results
- Novo Nordisk is raising its full-year outlook as its weight loss pill keeps selling
- Novo Nordisk's raised forecast fails to change the debate over its obesity business
- Eli Lilly stock jumps after late-stage trial of next-generation weight-loss drug